Clinical Trials Browser

Carcinoma, Transitional Cell × sapanisertib × 90 days × Clear all

NCT03047213 2026-05-13

Sapanisertib in Treating Patients With Locally Advanced or Metastatic Bladder Cancer With TSC1 and/or TSC2 Mutations

Phase 2 Active not recruiting

17 enrolled 11 charts

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell